Actuate Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Actuate Therapeutics' lead drug candidate, elraglusib, demonstrated a statistically significant improvement in median overall survival for metastatic pancreatic cancer in a Phase 2 trial.
NASDAQ
Actuate Therapeutics' 10-K filing highlights positive interim Phase 2 results for elraglusib in mPDAC and outlines plans for future clinical trials and development.